Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2010 (2010), Article ID 953537, 17 pages
Review Article

Nanotargeted Radionuclides for Cancer Nuclear Imaging and Internal Radiotherapy

1Center of Nanomedicine and National Institute of Cancer Research, National Health Research Institutes, 35053 Miaoli, Taiwan
2Isotope Application Division, Institute of Nuclear Energy Research, 32546 Taoyuan, Taiwan
3Biomedical Imaging and Radiological Sciences, National Yang-Ming University, 11221 Taipei, Taiwan

Received 13 April 2010; Accepted 15 June 2010

Academic Editor: David J. Yang

Copyright © 2010 Gann Ting et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Current progress in nanomedicine has exploited the possibility of designing tumor-targeted nanocarriers being able to deliver radionuclide payloads in a site or molecular selective manner to improve the efficacy and safety of cancer imaging and therapy. Radionuclides of auger electron-, -, -, and -radiation emitters have been surface-bioconjugated or after-loaded in nanoparticles to improve the efficacy and reduce the toxicity of cancer imaging and therapy in preclinical and clinical studies. This article provides a brief overview of current status of applications, advantages, problems, up-to-date research and development, and future prospects of nanotargeted radionuclides in cancer nuclear imaging and radiotherapy. Passive and active nanotargeting delivery of radionuclides with illustrating examples for tumor imaging and therapy are reviewed and summarized. Research on combing different modes of selective delivery of radionuclides through nanocarriers targeted delivery for tumor imaging and therapy offers the new possibility of large increases in cancer diagnostic efficacy and therapeutic index. However, further efforts and challenges in preclinical and clinical efficacy and toxicity studies are required to translate those advanced technologies to the clinical applications for cancer patients.